Evidence map›Paper›PMID 36830797›Full record

ArticleBiomedicines2023

Gene Therapy with p14/tBID Induces Selective and Synergistic Apoptosis in Mutant Ras and Mutant p53 Cancer Cells In Vitro and In Vivo.

Robert L Fine, Yuehua Mao, Dario Garcia-Carracedo, Gloria H Su, Wanglong Qiu, Uri Hochfeld, Gwen Nichols, Yong-Liang Li, Richard D Dinnen, Anthony Raffo and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Robert L FineExperimental Therapeutics Program, Division of Medical Oncology, The Pancreas Center at Columbia, Herbert Irving Comprehensive Cancer Center, NYPH-Columbia University Medical Center, New York, NY 10032, USA.
Yuehua MaoExperimental Therapeutics Program, Division of Medical Oncology, The Pancreas Center at Columbia, Herbert Irving Comprehensive Cancer Center, NYPH-Columbia University Medical Center, New York, NY 10032, USA.
Dario Garcia-CarracedoDepartment Pathology and Otolaryngology, Herbert Irving Comprehensive Cancer Center, NYPH-Columbia University Medical Center, New York, NY 10032, USA.ORCID 0000-0002-3263-8231
Gloria H SuDepartment Pathology and Otolaryngology, Herbert Irving Comprehensive Cancer Center, NYPH-Columbia University Medical Center, New York, NY 10032, USA.
Wanglong QiuDepartment Pathology and Otolaryngology, Herbert Irving Comprehensive Cancer Center, NYPH-Columbia University Medical Center, New York, NY 10032, USA.
Uri HochfeldExperimental Therapeutics Program, Division of Medical Oncology, The Pancreas Center at Columbia, Herbert Irving Comprehensive Cancer Center, NYPH-Columbia University Medical Center, New York, NY 10032, USA.
Gwen NicholsExperimental Therapeutics Program, Division of Medical Oncology, The Pancreas Center at Columbia, Herbert Irving Comprehensive Cancer Center, NYPH-Columbia University Medical Center, New York, NY 10032, USA.
Yong-Liang LiDepartment of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY 10032, USA.
Richard D DinnenExperimental Therapeutics Program, Division of Medical Oncology, The Pancreas Center at Columbia, Herbert Irving Comprehensive Cancer Center, NYPH-Columbia University Medical Center, New York, NY 10032, USA.
Anthony RaffoExperimental Therapeutics Program, Division of Medical Oncology, The Pancreas Center at Columbia, Herbert Irving Comprehensive Cancer Center, NYPH-Columbia University Medical Center, New York, NY 10032, USA.
Paul W Brandt-RaufDepartment of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY 10032, USA.
Columbia University Irving Medical Center · USUniversity of Illinois Chicago · US

Funding

Mouse Model for Human Pancreatic Ductal AdenocarcinomaR01CA109525 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SU, GLORIA HUEI-TING · 2004 to 2015
$2.6M
Predicting pancreatic cancer responses for a Parp inhibitor-based clinical trialRC2CA148346 · NCI · JOHNS HOPKINS UNIVERSITY · PI GOGGINS, MICHAEL G. · 2009 to 2010
$1.9M
ACL HHS R01OH007590NCI NIH HHS R01 CA109525NCI NIH HHS RC2 CA148346NIOSH CDC HHS R01 OH007590
6 · The paper itself

Abstract

Any gene therapy for cancer will be predicated upon its selectivity against cancer cells and non-toxicity to normal cells. Therefore, safeguards are needed to prevent its activation in normal cells. We designed a minimal p14

Indexed as

apoptosisgene therapyp14p14ARF promoterp53RastBID

Identifiers

PMID36830797
PMCPMC9953161
OpenAlexW4317506044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.